生物学标志物在肝细胞癌中的预后价值研究进展  

Advances of biomarkers for prognostic value in hepatocellular carcinoma

作　　者：戚德涛 李娟[2] 张岭漪[2] QI Detao;LI Juan;ZHANG Lingyi(The Second Clinical Medical College of Lanzhou University,Lanzhou 730000;Department of Hepatology,Lanzhou University Second Hospital,China)

机构地区：[1]兰州大学第二临床医学院,甘肃兰州730000 [2]兰州大学第二医院肝病科

出　　处：《胃肠病学和肝病学杂志》2024年第11期1575-1580,共6页Chinese Journal of Gastroenterology and Hepatology

基　　金：甘肃省自然科学基金(23JRRA0974)。

摘　　要：我国肝细胞癌(hepatocellular carcinoma,HCC)的疾病负担较重。尽管当前包含手术切除、射频消融、经导管肝动脉化疗栓塞、放射治疗、分子靶向治疗、免疫治疗、肝移植的综合治疗体系已日趋完善,但由于肿瘤异质性等多因素影响,不同HCC患者的预后各不相同。近年来,传统与新型生物学标志物在肝细胞中预后价值的研究为我们研究HCC提供了新的视角和思路,故本文对蛋白、细胞、基因不同水平生物学标志物在HCC中的预后价值作一综述。The disease burden of hepatocellular carcinoma(HCC)in China is relatively heavy.The comprehensive treatment system including surgery,radiofrequency ablation,transcatheter arterial chemoembolization,radiation therapy,molecular targeted therapy,immunotherapy and liver transplant is gradually improving.Patients have differential outcome due to the influence of various factors such as intratumor.These studies on traditional and novel biological markers provide some new ideas for exploring HCC.The article reviewed the advances in clinical applications of biological biomarkers from different levels in HCC.

关 键 词：肝细胞癌 糖蛋白 单细胞RNA测序 液体活检 肠道微生物 

分 类 号：R735.7[医药卫生—肿瘤]